Valeant CEO Michael Pearson has never been a fan of drug R&D. Openly caustic in the past about the risk involved in drug research, Valeant’s chief executive has largely steered clear of developing a pipeline, focusing instead on a clear strategy involving the rapid acquisition of marketed drugs.

…read more

Source: Longtime R&D critic Valeant finds itself with a growing pipeline, and a setback


0 No comments